NEFL and Huntington disease: To our knowledge, the relationship observed between MI and plasma NfL at baseline represents the first data in Huntington’s disease patients relating non-invasive 1H-MRS measures to an established biofluid marker of disease progression and further highlights the relationship between increased neuroinflammatory response and neurodegenerative processes in Huntington’s disease.